GlaxoSmithKline plc Market Cap ($108.32 Billion)
Market Cap & Net Worth: GlaxoSmithKline plc (GSKN)
GlaxoSmithKline plc market cap. GlaxoSmithKline plc (MX:GSKN) has a market capitalization of $108.32 Billion (MX$1.88 Trillion) as of November 5, 2026. Listed on the MX stock exchange, this Mexico-based company holds position #229 globally and #9 in its home market, demonstrating a 7.32% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GlaxoSmithKline plc's stock price MX$938.00 by its total outstanding shares 2006642158 (2.01 Billion). Also see GlaxoSmithKline plc cash conversion from operations for how efficiently the company converts equity into cash flow.
GlaxoSmithKline plc Market Cap History (2015–2026)
GlaxoSmithKline plc market cap history from 2015 to 2026. Data shows growth from $64.88 Billion to $108.32 Billion (5.01% CAGR). Check GSKN live share price for real-time trading data and today's change.
GlaxoSmithKline plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GlaxoSmithKline plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore GSKN net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.39x
GlaxoSmithKline plc's market cap is 2.39 times its annual revenue
Latest Price to Earnings (P/E) Ratio
29.15x
GlaxoSmithKline plc's market cap is 29.15 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $64.88 Billion | $23.92 Billion | $8.42 Billion | 2.71x | 7.70x |
| 2016 | $81.44 Billion | $27.89 Billion | $912.00 Million | 2.92x | 89.29x |
| 2017 | $71.42 Billion | $30.19 Billion | $1.53 Billion | 2.37x | 46.62x |
| 2018 | $85.25 Billion | $30.82 Billion | $3.62 Billion | 2.77x | 23.53x |
| 2019 | $101.06 Billion | $33.75 Billion | $4.64 Billion | 2.99x | 21.76x |
| 2020 | $89.43 Billion | $34.10 Billion | $5.75 Billion | 2.62x | 15.56x |
| 2021 | $117.06 Billion | $34.11 Billion | $4.38 Billion | 3.43x | 26.70x |
| 2022 | $72.36 Billion | $29.32 Billion | $14.96 Billion | 2.47x | 4.84x |
| 2023 | $69.60 Billion | $30.33 Billion | $4.93 Billion | 2.29x | 14.12x |
| 2024 | $75.06 Billion | $31.38 Billion | $2.58 Billion | 2.39x | 29.15x |
Competitor Companies of GSKN by Market Capitalization
Companies near GlaxoSmithKline plc in the global market cap rankings as of November 5, 2026. Also see GSKN total asset value for a full breakdown of the balance sheet.
Key companies related to GlaxoSmithKline plc by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #14 globally with a market cap of $1.06 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #43 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #14 | Eli Lilly and Company | NYSE:LLY | $1.06 Trillion | $1409.38 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $266.17 |
| #43 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $286.00 |
Market Capitalization of GlaxoSmithKline plc (2015–2026)
Market capitalization of GlaxoSmithKline plc from 2015 to today. Between 2015 and today, GlaxoSmithKline plc's market cap moved from $64.88 Billion to $ 108.32 Billion, with a yearly change of 5.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | MX$108.32 Billion | +8.56% |
| 2025 | MX$99.78 Billion | +32.92% |
| 2024 | MX$75.06 Billion | +7.85% |
| 2023 | MX$69.60 Billion | -3.82% |
| 2022 | MX$72.36 Billion | -38.18% |
| 2021 | MX$117.06 Billion | +30.90% |
| 2020 | MX$89.43 Billion | -11.51% |
| 2019 | MX$101.06 Billion | +18.55% |
| 2018 | MX$85.25 Billion | +19.37% |
| 2017 | MX$71.42 Billion | -12.30% |
| 2016 | MX$81.44 Billion | +25.53% |
| 2015 | MX$64.88 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of GlaxoSmithKline plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $108.32 Billion USD |
| MoneyControl | $108.32 Billion USD |
| MarketWatch | $108.32 Billion USD |
| marketcap.company | $108.32 Billion USD |
| Reuters | $108.32 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GlaxoSmithKline plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more